Congestive Vascular Failure Treatment market: Congestive vascular failure develops when ventricles unable to pump enough volume of blood to the body. Increase in the prevalence of cardiovascular diseases across regions is the major factors expected to drive the revenue growth of congestive vascular failure treatment globally. Lifestyle-related factors are expected to add to the growing disease incidence of CVDs. In addition, the growing number of obese patients is expected to bolster the congestive heart failure treatment market. The huge treatment demand for congestive vascular failure is expected to boost the treatment market. However, the availability of the generic drugs and lack of end-stage pipeline drugs and therapies for congestive vascular failure treatment is about to hinder the market.

Congenital Vascular Disease market report evaluated the historical and current performance of the market, especially highlighting the key trends and growth opportunities. Congenital Heart Disease market report discussed the present scenario of market size with respect to volume and share. Congenital Vascular Disease market report contains the growth pattern by the company, applications, types, and regions from 2019 - 2023. Congenital Vascular Disease market report also covers an in-depth analysis of the competitive landscape, future development trends, and key manufacturers of the industry. The factors driving the global market growth of the congenital vascular disease are rising prevalence of congenital vascular disease & the rise in the adoption of minimally invasive procedures. Further, many Influenced market players, growing demand for catheterization & application of cardiac biomarkers in congenital vascular disease treatment are also considered as a major factor for driving the growth of the global congenital vascular disease market during the forecast period.

Market Highlights
• Increasing disease prevalence and uptake of branded therapies will result in considerable growth of the CHF market over the 2017–26 forecast period, with sales, increasing from $2.9bn to $8.3bn.
• Entresto has now overcome initial barriers in the form of reimbursement delays and physicians’ reluctance to shift from traditional treatment practices. Its sales have risen to over $1,028m in 2018, primarily driven by the class I recommendation in US and EU treatment guidelines.
• Current treatment practices for CHF are dominated by generic therapies, placing pressure on the pipeline to demonstrate strong cost/efficacy profiles.
• Despite the dominance of generics, there is significant commercial potential for novel therapies that demonstrate a benefit in patients with CHF with preserved ejection fraction, which accounts for 50% of the CHF population. This is a major unmet need as the heterogeneous nature of the disease renders it difficult to identify promising modes of action.
• The high co-occurrence of diabetes with CHF means that the cardiovascular benefit of SGLT-2 inhibitors could facilitate significant uptake in this population. Studies investigating use in non-diabetic populations could further expand the target population.

Vascular Failure Market to ascend to $11.8 Billion by 2025:
The vascular failure market is set to rise from approx. $3.2 billion in 2015 to $11.8 billion by 2025, representing a compound annual growth rate of 13.7%, according to research and consulting firm Global Data.

Understanding the changing cardiovascular market:
1. Increasing demand for value
2. The rising uptake of innovative treatment technologies
3. Growing digital solutions adoption
4. Changing MedTech competitive landscape
5. Evolving provider and care delivery shifts

**Cardiovascular Market Insights:**
- Improving medical imaging and robotic-assisted surgeries are major factors contributing to the growth of the cardiovascular catheters market.
- Several segments within the cardiovascular drugs market are poised for steady growth, including the market for hypertension drugs.
- An increasing number of M&A and strategic collaborations, as well as the increasing adoption of portable cardiac monitoring devices, are the key trends expected to positively impact the global cardiac monitoring market through 2021.

**Global Interventional Cardiology Market to hit $24.96 Billion by 2027:**
As stated in a New market intelligence report by BIS Research, titled 'Global Interventional Cardiology Market - Analysis and Forecast, 2018-2027', the global interventional cardiology market was estimated at $14.69 billion in 2017, & is estimated to reach $24.96 billion by 2027. The global interventional cardiology market is expected to grow at a CAGR of 8.37% between the years 2018 & 2027, which is aided by the impressive growth of healthcare budgetary allocation and technological advancements in the medical device industry. Moreover, the rising prevalence of cardiac diseases & a growing geriatric population are the main factors leading to the growth of the market.

As a result, several companies are making arduous efforts by innovating new products or redesigning existing devices to attain better process efficiency. Therefore, to sustain in the highly competitive market, interventional cardiology is gradually becoming an indispensable solution for the medical device industry. Moreover, with the advancement in technology, factors such as an increase in patient awareness for advanced medical devices and a rise in the occurrence of lifestyle disorders are expected to actively drive the growth of the interventional cardiology market during the period of 2018 to 2027.

**Highlights:**
Interventional cardiology procedure of primary angioplasty is regarded as the gold standard of care for acute myocardial infarction. The emergence of interventional cardiology devices has enabled the efficient treatment of ischemic vascular disease, percutaneous coronary intervention (angioplasty), stent placement, coronary thrombectomy, valve disease (valvuloplasty, percutaneous valve repair or replacement), and congenital heart abnormalities. The main advantage of using advanced cardiac intervention devices is that the procedure eliminates the risk of scars and pain and reduces the post-operative recovery time. The advanced interventional cardiology device market is expected to grow at a CAGR of 8.37% from 2018 to 2027. In this, the optical coherent tomography segmented is expected to grow at the highest CAGR of 9.30% from 2018 to 2027. The global interventional cardiology market comprises substantial investments made by several conglomerate and small-medium enterprises. More than 400 products from about 100 companies are available in the market. The ambulatory surgical center segment is expected to witness a robust CAGR of 5.99% in the forecast period 2018-2027.

**Global Interventional Cardiology Market: Focus on Devices, End Users, Regions- Analysis and Forecast from 2018 to 2027:**
The global interventional cardiology market was estimated at $14.69 billion in 2017 and is anticipated to reach $24.96 billion by 2027. With the rise in the demand for advanced medical devices to treat cardiovascular diseases, increasing geriatric population with higher life expectancy, and new product launches by
several conglomerate companies, the cardiac intervention market is expected to witness moderate growth. The emergence of advanced imaging modalities such as IntraVenous UltraSound (IVUS), Optical Coherent Tomography (OCT), and Fractional Flow Reserve (FFR) has led to the growth of the market.

The global interventional cardiology is segmented by the geographical regions into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW). North America is the leading contributor to the global interventional cardiology market. However, the Asia-Pacific is expected to grow at a CAGR of 7.12% in the forecast period 2018-2027. The global interventional cardiology market for advanced devices is majorly dominated by the U.S. and the European players. The key players who have significant contributions to the global interventional cardiology market are Abiomed, Inc., ACIST Medical Systems, Inc., B. Braun Melsungen AG, Biotronik SE & Co. KG, Edwards Lifesciences Corporation, Life Vascular Devices Biotech S.L., Boston Scientific Corporation, C. R. Bard, Inc., Biosensors International Group, Ltd., Cook Medical LLC, Cordis Corporation, GE Healthcare, Biostense Webster, Inc., Medtronic Plc, Merit Medical Systems, Inc., Novacam Technologies Inc., Koninklijke Philips N.V., St. Jude Medical, Terumo Corporation, and W.L. Gore & Associates, Inc., among others.

**Top drivers behind cardiovascular market growth by 2024:**

According to estimates published by Global Data’s Pharma Intelligence Center, total sales for cardiovascular disease drugs will grow steadily over the next 6 years, from almost $47 billion in 2018 to over $70 billion in 2024.